BLUTH BIO INDUSTRIES
  • BLUTH BIO INDUSTRIES
  • TEAM
  • Technologies
    • Therapeutics >
      • SOPHOROLIPIDS FOR THE TREATMENT OF ASTHMA
      • RECIPROCAL SERUM/PLASMA EXCHANGE FOR TREATMENT OF CANCER
      • PANCREATITIS ASSOCIATED PROTEINS (PAP) FOR TREATMENT OF PANCREATITIS
      • REGENERATION (REG) PROTEINS FOR THE TREATMENT OF DIABETES
      • STEM CELL THERAPY FOR DIABETES
      • IMMUNEX – RECOMBINANT HUMAN IgGFc FOR THE TREATMENT OF AUTOIMMUNE DISEASE
    • Diagnostics >
      • BIOMARKER (BLOOD TEST) DEVELOPMENT AND COMMERCIALIZATION PLATFORM
      • BLOOD TEST FOR DETECTION OF PANCREATIC CANCER
    • Devices >
      • Pheonix TM needle
      • Scratchless Scope TM
      • Bottle Buddy TM
    • Services >
      • Bluth Bio Consulting LLC
      • Publication and Grant Review Services
      • Business of Healthcare
      • Medical Martial Arts
  • News
  • SELECT PUBLICATIONS
  • CONTACT
  • Relationships
BLOOD TEST FOR DETECTION OF PANCREATIC CANCER
 
Background: Pancreatic cancer kills ~30,000 patients a year. Most patients die ~1 year after diagnosis despite aggressive therapy. The problem is that most patients are diagnosed at late stage disease and are therefore not candidates for surgical intervention (resection). As such there is an urgent need for blood tests which can diagnose cancer early when treatment can be more effective.

Pancreatic cancer market.

Ø      Fifth leading cause of cancer death in US (1st is heart disease)

Ø      Five year survival rate of <4%.

Ø      Cost of pancreatic cancer industry is $1 billion is USA

Ø       No current early detection blood test available

Clinical Data:  This new blood test has been tested on pancreatic cancer patients (confirmed by biopsy) and was significantly elevated compared with healthy controls.

IP: patents are being filed for testing methodology and disease application.

Powered by Create your own unique website with customizable templates.